Abstract
Background Illicit cigarette trade has significant economic and public health implications. It leads to governments tax revenue losses due to the evasion of tobacco taxes, and often these cigarettes are cheaper ones therefore increasing cigarette consumption.
Objective To estimate the Illicit cigarette trade and tax evasion in Zambia and establish its associated factors
Methods and analysis A cross sectional survey was used to collect empty cigarette packs from the retailers and street/bins in 25 districts covering 10 Provinces of Zambia. We used a descriptive analysis to calculate the proportion of illicit cigarette packs and other specific criteria. Logistic regression was used to model the factors associated with the prevalence of the illicit cigarette market in Zambia.
Results Of the 118, 344 empty cigarette packs collected (82.0% from the retailers and 18.0% the street/bins), Rothmans accounted for 40.7% and Stuyvesant 13.1%, both manufactured by British American Tobacco. 14,428 (12.2%) were deemed illicit. Out of the total packs, 1792 (1.5%) did not have a textual health warning, 343 (0.3%) packs did not have a textual health warning in english, 1490 (1.3%) had duty-free stamps even though they were purchased from retail outlets that were not duty-free shops and, 11,939 (10.1%) did not have a ZRA stamp. Factors associated with reduced odds of illicit cigarettes sales were non-boarder [AOR 0.17 (CI; 0.13 – 0.23)] and local manufactured AOR 0.44 (CI; 0.37 – 0.53).
Conclusions Our study demonstrated that 12.2% of the cigarettes sold on the Zambian market is illicit, with 10.1% evading tax. We found that cigarettes from Lusaka province, urban regions, border towns, and those that are imported had higher odds of being illicit. This finding underscores the fact that Zambia should ratify and implement the WHO Protocol on Illicit Tobacco Trade (ITP) to counter the supply of illicit cigarettes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Melinda and Bill Gates
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the University of Zambia Biomedical Research Ethics Committee (UNZABREC) (REF 3288-2022) and permission to conduct the study was obtained from the National Health Research Authority (NHRA) (REF-NHRA 0000002/2/11/2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
The data sets used and/ or analyzed during the current study is available at the zenodo link 10.5281/zenodo.10993175
